Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity

Although the sodium channel blocker, mexiletine, is the first choice drug in myotonia, some myotonic patients remain unsatisfied due to contraindications, lack of tolerability, or incomplete response. More therapeutic options are thus needed for myotonic patients, which require clinical trials based...

Descripción completa

Detalles Bibliográficos
Autores principales: De Bellis, Michela, Carbonara, Roberta, Roussel, Julien, Farinato, Alessandro, Massari, Ada, Pierno, Sabata, Muraglia, Marilena, Corbo, Filomena, Franchini, Carlo, Carratù, Maria Rosaria, De Luca, Annamaria, Conte Camerino, Diana, Desaphy, Jean-François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pergamon Press 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154332/
https://www.ncbi.nlm.nih.gov/pubmed/27743929
http://dx.doi.org/10.1016/j.neuropharm.2016.10.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154332/
https://www.ncbi.nlm.nih.gov/pubmed/27743929
http://dx.doi.org/10.1016/j.neuropharm.2016.10.013

Ejemplares similares